Referências:
- Primary outcome analysis of the phase 3 SONIA trial (BOOG
2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6
(CDK4/6) inhibitors for patients with hormone receptor-positive (HR+),
HER2-negative (HER2-) advanced breast cancer (ABC). DOI:
10.1200/JCO.2023.41.17_suppl.LBA1000 Journal of Clinical Oncology 41, no.
17_suppl (June 10, 2023) LBA1000-LBA1000. Published online June 07, 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.17_suppl.LBA1000?role=tab - A randomized controlled trial comparing primary tumor
resection plus systemic therapy with systemic therapy alone in metastatic
breast cancer (PRIM-BC): Japan Clinical Oncology Group study JCOG1017. DOI:
10.1200/JCO.2023.41.16_suppl.523 Journal of Clinical Oncology 41,
no. 16_suppl (June 01, 2023) 523-523. Published online May 31, 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.523
